IO Biotech

IO Biotech Minority Interest

Minority Interest (Non-Controlling Interest) of IO Biotech (IOBT) as of Oct 20, 2026.

Minority Interest

-USD

Last updated:

Minority Interest (Non-Controlling Interest) of IO Biotech is 2026 - USD. Minority Interest (Non-Controlling Interest) of IO Biotech was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IO Biotech Stock analysis

What does IO Biotech do? IO Biotech Inc, based in Copenhagen, Denmark, operates in the Health Care sector, specializing in Biotechnology. The company develops immune modulating cancer therapies using its T-win technology platform, focusing on disrupting tumor-induced immunosuppression. Its lead product candidate, IO102-IO103, targets immunosuppressive proteins like IDO and PD-L1. Founded as a spin-off from the National Cancer Center Immune Therapy at Herlev University Hospital, IO Biotech has 57 employees and is listed on the stock exchange since November 5, 2021. IO Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IO Biotech stock

On Eulerpool you can find the complete historical development of Minority Interest (Non-Controlling Interest) IO Biotech since 2006 – with annual values, charts, and detailed analysis.

Minority interest represents the portion of subsidiaries not owned by the parent company. It reflects third-party ownership stakes in consolidated entities.

Minority Interest (Non-Controlling Interest)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Minority Interest (Non-Controlling Interest)'s IO Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IO Biotech

All Key Metrics — IO Biotech